SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT00260520

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Low Molecular Weight Heparin Vs No Treatment in Pregnant Women With Previous Preeclampsia or Fetal Growth Restriction Who Were Heterozygote for Factor V Leiden or Prothrombin Gene G20210A Mutation

The objective of this trial will be to determine whether prophylactic low-molecular weight heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A prothrombin gene mutations thrombophilia and a history of severe preeclampsia and/or severe fetal growth restriction reduces the risk of the composite outcome of preeclampsia, fetal growth restriction, or both.

NCT00260520 Preeclampsia
MeSH:Pre-Eclampsia Fetal Growth Retardation
HPO:Intrauterine growth retardation Preeclampsia Toxemia of pregnancy

1 Interventions

Name: Dalteparin

Type: Drug



There is one SNP

SNPs


1 G20210A

Low Molecular Weight Heparin Vs No Treatment in Pregnant Women With Previous Preeclampsia or Fetal Growth Restriction Who Were Heterozygote for Factor V Leiden or Prothrombin Gene G20210A Mutation. --- G20210A ---

LMWH to Prevent Preeclampsia and Fetal Growth Restriction The objective of this trial will be to determine whether prophylactic low-molecular weight heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A prothrombin gene mutations thrombophilia and a history of severe preeclampsia and/or severe fetal growth restriction reduces the risk of the composite outcome of preeclampsia, fetal growth restriction, or both. --- G20210A ---

Inclusion Criteria: - Previous severe preeclampsia - Previous severe fetal growth restriction - Heterozygous Factor V Leiden - Heterozygous G20210A prothrombin gene mutations Exclusion Criteria: - renal disease - chronic hypertension - preexisting diabetes mellitus - homozygosity for Factor V Leiden - homozygosity for prothrombin G20210A mutation - hyperhomocysteinemia - protein C deficency - protein S deficency - antithrombin deficiency - positive anticardiolipin antibodies - positive lupus anticoagulant Inclusion Criteria: - Previous severe preeclampsia - Previous severe fetal growth restriction - Heterozygous Factor V Leiden - Heterozygous G20210A prothrombin gene mutations Exclusion Criteria: - renal disease - chronic hypertension - preexisting diabetes mellitus - homozygosity for Factor V Leiden - homozygosity for prothrombin G20210A mutation - hyperhomocysteinemia - protein C deficency - protein S deficency - antithrombin deficiency - positive anticardiolipin antibodies - positive lupus anticoagulant Preeclampsia Pre-Eclampsia Fetal Growth Retardation The objective of this trial will be to determine whether prophylactic low-molecular weight heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A prothrombin gene mutations thrombophilia and a history of severe preeclampsia and/or severe fetal growth restriction reduces the risk of the composite outcome of preeclampsia, fetal growth restriction, or both. --- G20210A ---

Inclusion Criteria: - Previous severe preeclampsia - Previous severe fetal growth restriction - Heterozygous Factor V Leiden - Heterozygous G20210A prothrombin gene mutations Exclusion Criteria: - renal disease - chronic hypertension - preexisting diabetes mellitus - homozygosity for Factor V Leiden - homozygosity for prothrombin G20210A mutation - hyperhomocysteinemia - protein C deficency - protein S deficency - antithrombin deficiency - positive anticardiolipin antibodies - positive lupus anticoagulant Inclusion Criteria: - Previous severe preeclampsia - Previous severe fetal growth restriction - Heterozygous Factor V Leiden - Heterozygous G20210A prothrombin gene mutations Exclusion Criteria: - renal disease - chronic hypertension - preexisting diabetes mellitus - homozygosity for Factor V Leiden - homozygosity for prothrombin G20210A mutation - hyperhomocysteinemia - protein C deficency - protein S deficency - antithrombin deficiency - positive anticardiolipin antibodies - positive lupus anticoagulant Preeclampsia Pre-Eclampsia Fetal Growth Retardation The objective of this trial will be to determine whether prophylactic low-molecular weight heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A prothrombin gene mutations thrombophilia and a history of severe preeclampsia and/or severe fetal growth restriction reduces the risk of the composite outcome of preeclampsia, fetal growth restriction, or both. --- G20210A --- --- G20210A ---

Inclusion Criteria: - Previous severe preeclampsia - Previous severe fetal growth restriction - Heterozygous Factor V Leiden - Heterozygous G20210A prothrombin gene mutations Exclusion Criteria: - renal disease - chronic hypertension - preexisting diabetes mellitus - homozygosity for Factor V Leiden - homozygosity for prothrombin G20210A mutation - hyperhomocysteinemia - protein C deficency - protein S deficency - antithrombin deficiency - positive anticardiolipin antibodies - positive lupus anticoagulant Inclusion Criteria: - Previous severe preeclampsia - Previous severe fetal growth restriction - Heterozygous Factor V Leiden - Heterozygous G20210A prothrombin gene mutations Exclusion Criteria: - renal disease - chronic hypertension - preexisting diabetes mellitus - homozygosity for Factor V Leiden - homozygosity for prothrombin G20210A mutation - hyperhomocysteinemia - protein C deficency - protein S deficency - antithrombin deficiency - positive anticardiolipin antibodies - positive lupus anticoagulant Preeclampsia Pre-Eclampsia Fetal Growth Retardation The objective of this trial will be to determine whether prophylactic low-molecular weight heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A prothrombin gene mutations thrombophilia and a history of severe preeclampsia and/or severe fetal growth restriction reduces the risk of the composite outcome of preeclampsia, fetal growth restriction, or both. --- G20210A --- --- G20210A --- --- G20210A ---

Inclusion Criteria: - Previous severe preeclampsia - Previous severe fetal growth restriction - Heterozygous Factor V Leiden - Heterozygous G20210A prothrombin gene mutations Exclusion Criteria: - renal disease - chronic hypertension - preexisting diabetes mellitus - homozygosity for Factor V Leiden - homozygosity for prothrombin G20210A mutation - hyperhomocysteinemia - protein C deficency - protein S deficency - antithrombin deficiency - positive anticardiolipin antibodies - positive lupus anticoagulant Inclusion Criteria: - Previous severe preeclampsia - Previous severe fetal growth restriction - Heterozygous Factor V Leiden - Heterozygous G20210A prothrombin gene mutations Exclusion Criteria: - renal disease - chronic hypertension - preexisting diabetes mellitus - homozygosity for Factor V Leiden - homozygosity for prothrombin G20210A mutation - hyperhomocysteinemia - protein C deficency - protein S deficency - antithrombin deficiency - positive anticardiolipin antibodies - positive lupus anticoagulant Preeclampsia Pre-Eclampsia Fetal Growth Retardation The objective of this trial will be to determine whether prophylactic low-molecular weight heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A prothrombin gene mutations thrombophilia and a history of severe preeclampsia and/or severe fetal growth restriction reduces the risk of the composite outcome of preeclampsia, fetal growth restriction, or both. --- G20210A --- --- G20210A --- --- G20210A --- --- G20210A ---

Inclusion Criteria: - Previous severe preeclampsia - Previous severe fetal growth restriction - Heterozygous Factor V Leiden - Heterozygous G20210A prothrombin gene mutations Exclusion Criteria: - renal disease - chronic hypertension - preexisting diabetes mellitus - homozygosity for Factor V Leiden - homozygosity for prothrombin G20210A mutation - hyperhomocysteinemia - protein C deficency - protein S deficency - antithrombin deficiency - positive anticardiolipin antibodies - positive lupus anticoagulant Inclusion Criteria: - Previous severe preeclampsia - Previous severe fetal growth restriction - Heterozygous Factor V Leiden - Heterozygous G20210A prothrombin gene mutations Exclusion Criteria: - renal disease - chronic hypertension - preexisting diabetes mellitus - homozygosity for Factor V Leiden - homozygosity for prothrombin G20210A mutation - hyperhomocysteinemia - protein C deficency - protein S deficency - antithrombin deficiency - positive anticardiolipin antibodies - positive lupus anticoagulant Preeclampsia Pre-Eclampsia Fetal Growth Retardation The objective of this trial will be to determine whether prophylactic low-molecular weight heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A prothrombin gene mutations thrombophilia and a history of severe preeclampsia and/or severe fetal growth restriction reduces the risk of the composite outcome of preeclampsia, fetal growth restriction, or both. --- G20210A --- --- G20210A --- --- G20210A --- --- G20210A --- --- G20210A ---



HPO Nodes


HPO:
HP:0001511: Intrauterine growth retardation
Genes 602
SMC1A WHCR CTC1 ATP7A ABCC8 MYORG SLC20A2 ESCO2 POLR3A TRAIP TRAIP COQ2 SOX11 APPL1 TCTN3 XPR1 NUP133 INSR SKIV2L TTC37 OTUD6B BCR HYMAI ERCC2 EVC2 BRAF XRCC4 ERCC6 KCNJ11 STOX1 ABCC8 CTBP1 CEP290 SETD5 NDUFA10 BUB1 GFM2 IGF1R TINF2 KCNJ11 PIEZO2 RNU4ATAC ORC1 COG7 ZMPSTE24 PDE4D ASXL1 ADGRG6 GBA YY1 RAF1 NELFA GATA4 GLIS3 MYH3 TINF2 SUFU HDAC8 PDE4D FLVCR2 DOK7 POLA1 TBX1 ATP6V0A2 TERT TMEM70 NFIX KMT2A SMARCA4 ORC6 RBBP8 INS PIGG NDUFA6 NDUFS1 NDE1 ITPA INS GINS1 EIF2AK3 STN1 GLI2 SEMA5A CORIN UFD1 NHP2 CUL7 FGF8 PDX1 ARID2 TDGF1 B3GLCT FGFRL1 H19 NDUFB11 XRCC2 CHRNA1 FGFR3 CKAP2L POLE SIN3A PAX4 JMJD1C PALB2 PHGDH ND3 TRIM37 FMR1 NODAL INS TBCE SLC18A3 FANCE FUT8 NCAPG2 RFX6 HMGA2 NDUFS2 RTTN SOX4 NDUFAF5 MKS1 PTPN11 RAD51 HES7 PSAT1 KANSL1 PCNT FBN1 AARS1 ATR IBA57 DONSON JAG1 COQ4 SEC24C DHDDS STT3B SMC1A HYMAI ARID1A B3GLCT BCAP31 ERCC6 FANCD2 EVC ZIC2 BLM IGF1 SMARCB1 NIN ERCC2 RTEL1 ESCO2 PSAT1 WDR73 SDHB ABL1 GCK PRKDC RFWD3 MUSK GATA6 ERCC5 FANCL P4HB NDUFAF4 PHGDH WDR73 ACD TOP3A STRA6 FLT1 COMT HDAC6 MTRR NDUFB3 PRPS1 ERCC4 ZFP57 WASHC5 BCS1L CDC6 TUFM PDX1 RNF113A LIFR TBCE INSR DISP1 BLM TSFM FAM20C UNC80 CCDC8 CDK10 BRCA1 RERE CDKN1C PARN SMARCE1 RAB3GAP2 GATA4 FIG4 RFWD3 GLI1 ASXL1 ELN NUP88 TFAP2A CKAP2L ABCC8 TINF2 DKC1 SMARCA2 COQ9 KIF2A SIX3 WARS2 ZMPSTE24 FANCB MUSK ADAT3 TELO2 CEP57 DNAJC21 ABCC8 RREB1 BUB3 CTDP1 NDUFA11 SMARCE1 PSAT1 LFNG DYNC2LI1 NDUFAF2 FANCC GCK CDCA7 PLK4 MAD2L2 GATA5 PEX2 ERCC2 CDKN1C TBCE NDUFB9 NSDHL LEMD3 MCM4 ERCC5 TUBGCP4 BRCA2 FOXRED1 DLL1 SMARCC2 NDUFS7 TAPT1 WRAP53 GP1BB GLI3 RARB CEP57 PDE6D MCM5 PIEZO2 MAPK1 ERCC3 UQCC2 NDUFAF1 SNRPB SLC25A13 TERC COG5 DKC1 NSUN2 NBN SMARCB1 PPP1R15B UBR1 PHGDH RECQL4 IGF1 CDC6 NEK9 NKX2-6 FKTN ZFP57 HOXD13 CEL ZNF335 SDHD TERT NODAL CLCN7 NUS1 CTNND2 DNAJC19 NDUFA6 SC5D OSGEP DNAJC19 KDM6A SOX11 NDUFAF4 PIK3R1 RAB18 FLI1 PAH STAT3 ND2 LETM1 ATP6V0A2 GDF1 SMC3 NOS3 RB1 TBCE PSPH CNOT1 SEC24D PDE4D PLAGL1 INSR SIN3A CHD7 MESP2 ARID1B RBM10 GLI3 HDAC6 TBX4 UBE2T INS TGIF1 CHRND WDR4 XYLT1 DYRK1A PIGG ERCC1 TAF1 WNT4 LMNA SMARCAL1 PCDH12 ATP7A STRA6 YY1 NDUFS4 NDUFS3 RIPK4 GATA6 IGF1R ESCO2 DONSON TRAPPC11 WNT7A FANCL PDX1 SDHA DHCR24 RBM10 HIRA EXOSC9 TFAM NSD2 TBX1 LIG4 TUBGCP6 LAGE3 CHRNG NDUFS6 ARCN1 RAD21 FGFR1 HYMAI NDUFAF3 DPF2 STAG1 RIPPLY2 NDUFV1 ERCC8 BRIP1 BUB1B PEX5 HSD11B2 ALDH18A1 ALDH18A1 NIPBL FANCF ALG8 NKX2-5 PCGF2 TBC1D20 TMEM126B ACD GFM1 PPP1R15B ABCB7 ATP5F1A PDGFB DHCR7 BMPER FANCI BUB1B UNC80 WDR4 FAM111A DLL3 GCK POLE FGFR1 TGDS OBSL1 BRPF1 GAS1 SLC35A2 GTF2E2 TIMMDC1 IGHMBP2 PARN TTC37 GPKOW SHH FOXH1 NDUFAF5 COQ7 SLC25A24 DHCR7 HNF1A KIF5C GTF2E2 KCNJ11 USB1 CENPJ PLK4 TMEM216 PLK4 PTDSS1 NDUFS8 COG1 ND1 IGF2 FANCA ORC6 CDC45 SEC61A1 NSD2 GTF2H5 SON SKIV2L FANCM TARS1 RTEL1 BRIP1 CDKN1C SDHAF1 SF3B4 TINF2 PDSS2 NDUFB10 SMAD4 ATP6V1A MCTP2 PDGFRB TRIP13 UBR1 GATA6 RNF113A MPLKIP NALCN RTEL1 GMNN KIF14 TCTN3 ATR ALG1 LETM1 BRCA2 CENPE ORC4 NDUFB11 AFF2 PCNT RAD51C PCNT OTUD6B ARVCF LARS2 PLOD3 EMG1 RPL11 RNU4ATAC POLR3A RNU4ATAC PRKAR1A CCNQ FTO KCNJ11 ARID1B SIX2 SMARCAL1 KMT2A SAMD9 TMEM70 SLX4 NPM1 COG6 COG4 ERCC1 HHAT DKC1 ORC4 RNU4ATAC DDX11 RPS19 SLC26A2 TBX1 PUF60 TFAP2A SRCAP FLNB CENPJ PNPT1 MLXIPL ZFPM2 RAPSN FANCG FANCI PYCR1 STT3B NUBPL KLHL7 TRMT10A CENPE CEP152 PDX1 PTCH1 BLK RNASEH2A CITED2 PKLR TPRKB RPL10 POLA1 NEUROD1 CHRNG NDUFV2 GATAD2B RAB3GAP1 FANCB SFXN4 CPLX1 CUL7 HADH IARS1 VPS13B OSGEP ATRIP ORC1 ATP6V0A2 GTPBP3 CTC1 TTC7A TTC7A BCS1L NOP10 CTU2 SMARCA4 HYLS1 MBTPS2 PARN HNF4A NDUFB3 KLF11 NUP107 ALX4 TP53RK CRKL SLC25A24 CDON TALDO1 MYOD1 NIPBL PLAGL1 SEMA3E SMAD4 NIN NDUFA1 ARL6IP6 RERE GJA5 CDT1 QRICH1 ATP6V1E1 IFIH1 TBX6 LMNA SMC1A LAGE3 CDT1
Protein Mutations 1
G20210A
SNP 0